Drug intelligence / Profile preview

ATNC05

Development stage: Unknown
Lead developer: Allodynic Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ATNC05 is an investigational drug developed by Allodynic Therapeutics, Inc. It is being evaluated in a Phase II clinical trial for the treatment of Atypical Facial Pain (AFP), also known as Persistent Idiopathic Facial Pain (PIFP). The drug is administered orally in capsule form. Its mechanism of action is not disclosed in the provided context. The study specifically targets patients with chronic constant facial pain and excludes those with primarily paroxysmal pain.

Targets

MOR (Mu opioid receptor)ADRA2 (Adrenergic alpha-2 receptor family)

Beyond the preview

Go deeper on ATNC05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATNC05.

Explore the full profile